2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

2:30PM-4:00PM: Abstract Number: 1842

Patients and Relatives Coping with Inflammatory Arthritis: Impact of Communication, Social Support and Relatives Burden on Patients Perceived Health

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1824

Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus

3S082: SLE – Clinical II: Flares & Morbidity of SLE (1824–1829)

2:30PM-4:00PM: Abstract Number: 1803

Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina

4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: Abstract Number: 1805

Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study

4M090: Infection-Related Rheumatic Disease (1800–1805)

2:30PM-4:00PM: Abstract Number: 1845

Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1774

Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis

4M093: RA – Animal Models (1770–1775)

2:30PM-4:00PM: Abstract Number: 1843

Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study

4M127: Pain, Anxiety, & Depression (1842–1847)

2:30PM-4:00PM: Abstract Number: 1816

Psoriasis Associated with Anti-Tumor Necrosis Factor-Alpha Therapies in Children with Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis, and Chronic Noninfectious Osteomyelitis

4M092: Pediatric Rheumatology – Clinical II: JIA (1812–1817)

2:30PM-4:00PM: Abstract Number: 1832

Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis

4M097: Systemic Sclerosis & Related Disorder – Clinical II: Cardiopulmonary Involvement (1830–1835)

2:30PM-4:00PM: Abstract Number: 1841

Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1783

Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis

4M094: SLE – Animal Models (1782–1787)

2:30PM-4:00PM: Abstract Number: 1810

Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study

4M091: Miscellaneous Rheumatic & Inflammatory Disease II: Checkpoint Inhibitors-Induced & Other Rheumatic Conditions (1806–1811)

2:30PM-4:00PM: Abstract Number: 1797

Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees

4M089: Education (1794–1799)

2:30PM-4:00PM: Abstract Number: 1840

Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone

4M098: Vasculitis – Non-ANCA-Associated & Related Disorders II: Large Vessel Vasculitis Treatment (1836–1841)

2:30PM-4:00PM: Abstract Number: 1800

Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)

4M090: Infection-Related Rheumatic Disease (1800–1805)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].